Log in

Relevant bibliographies by topics / RFC 6815

Contents

Journal articles
Dissertations / Theses

Academic literature on the topic 'RFC 6815'

Author: Grafiati

Published: 28 June 2021

Last updated: 9 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'RFC 6815.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "RFC 6815"

1

Shiuan, Eileen, Anupama Reddy, Stephanie O. Dudzinski, et al. "Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma." Cancers 13, no. 6 (2021): 1475. http://dx.doi.org/10.3390/cancers13061475.

Full text

Abstract:

Predicting response to ICI therapy among patients with renal cell carcinoma (RCC) has been uniquely challenging. We analyzed patient characteristics and clinical correlates from a retrospective single-site cohort of advanced RCC patients receiving anti-PD-1/PD-L1 monotherapy (N = 97), as well as molecular parameters in a subset of patients, including multiplexed immunofluorescence (mIF), whole exome sequencing (WES), T cell receptor (TCR) sequencing, and RNA sequencing (RNA-seq). Clinical factors such as the development of immune-related adverse events (odds ratio (OR) = 2.50, 95% confidence i

APA, Harvard, Vancouver, ISO, and other styles

2

Que, Xuchu, and Sharon L. Reed. "Expression and characterization of a rac family protein kinase of Entamoeba histolytica." Molecular and Biochemical Parasitology 66, no. 1 (1994): 111–18. http://dx.doi.org/10.1016/0166-6851(94)90041-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Zhang, Ying, Jörg Ellinger, Manuel Ritter, and Ingo G. H. Schmidt-Wolf. "Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma." Cancers 12, no. 9 (2020): 2471. http://dx.doi.org/10.3390/cancers12092471.

Full text

Abstract:

There is growing interest in cytokine-induced killer (CIK) cells on the integrated therapy of patients with RCC, especially those in the late stage or refractory to conventional chemotherapy and radiotherapy. In this review, a total of 15 clinical studies including 681 patients enrolled in CIK cell immunotherapy were outlined. Three-hundred-and-eighty-two patients with RCC were treated with CIK cells alone or in combination with DC vaccination, targeted agents sunitinib or sorafenib, and the PD-1 inhibitor pembrolizumab. Significantly improved 3-year overall survival rate was reported in four

APA, Harvard, Vancouver, ISO, and other styles

4

Reddy, Madhumitha, Ahmet Bindayi, Zachary Hamilton, et al. "Oncologic and functional outcomes of radical and partial nephrecotmy in PT3A patholigically upstaged renal cell carcinoma: A multi-instituitional analysis." Journal of Clinical Oncology 36, no. 6_suppl (2018): 685. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.685.

Full text

Abstract:

685 Background: Radical Nephrectomy (RN) has been the standard of care for complex and locally advanced renal cell carcinoma (RCC). Efficacy of PN in the setting of pT3a pathologic upstaged disease is controversial. We compared oncologic and functional outcomes of RN and PN in patients with upstaged pT3a RCC. Methods: Multicenter retrospective analysis of patients with cT1−2N0M0 RCC undergoing RN or PN upstaged to pT3a postoperatively. Primary outcome was Overall Survival (OS), with secondary outcomes being Recurrence Free Survival (RFS) and eGFR < 60 at last follow-up. Results: 8185 patien

APA, Harvard, Vancouver, ISO, and other styles

5

Dabestani, Saeed, Christian Beisland, Grant Stewart, et al. "Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis." Journal of Clinical Oncology 37, no. 7_suppl (2019): 636. http://dx.doi.org/10.1200/jco.2019.37.7_suppl.636.

Full text

Abstract:

636 Background: Designing adjuvant trials is challenging because of uncertainties of prevalence and outcome of high-risk RCC despite use of validated risk scores. Methods: RECUR is a European multicenter database capturing patient and tumour characteristics, recurrence patterns and survival of all patients treated with (partial) nephrectomy for non-metastatic RCC from 2006 to 2011 at each participating center. We evaluated prevalence, DFS and OS of RCC according to eligibility criteria of adjuvant trials IMMotion 010 (NCT03024996, IM), Checkmate 914 (NCT03138512, CM), Keynote-564 (NCT03142334,

APA, Harvard, Vancouver, ISO, and other styles

6

Duarte, Cassandra, Nieves Martinez Chanza, Katharine Collier, et al. "Outcomes of patients with pancreatic-only oligometastatic renal cell carcinoma (RCC)." Journal of Clinical Oncology 38, no. 6_suppl (2020): 681. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.681.

Full text

Abstract:

681 Background: Patients (pts) with RCC and oligometastatic pancreas metastases are treated with pancreatectomy, stereotactic body radiation therapy (SBRT), or systemic therapy. The optimal approach is not clear. We aimed to evaluate the comparative efficacy of the modalities in terms of progression-free survival (PFS) and overall survival (OS). Methods: This IRB-approved, multi-institutional, retrospective study evaluated pts with pancreatic-only RCC metastasis without concurrent metastases elsewhere. Data on pt demographics, tumor characteristics, treatment, and outcomes were collected. PFS

APA, Harvard, Vancouver, ISO, and other styles

7

Shinder, Brian, Sinae Kim, Arnav Srivastava, et al. "Factors associated with clinical trial participation for patients with renal cell carcinoma." Journal of Clinical Oncology 38, no. 6_suppl (2020): 670. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.670.

Full text

Abstract:

670 Background: Clinical trials are critical for the development of new treatment paradigms for renal cell carcinoma (RCC). The primary objective of this study was to characterize the factors associated with clinical trial participation for patients with RCC. The secondary objective was to examine survival outcomes in the clinical trial and control cohorts. Methods: The National Cancer Database (NCDB) was queried for patients with RCC who were coded as having enrolled in a clinical trial. Trial patients were matched in a 1:5 ratio to controls from the same institution based on clinical stage.

APA, Harvard, Vancouver, ISO, and other styles

8

Muzaffar, Mahvish, Abdul Rafeh Naqash, Darla K. Liles, and Sumyra Kachru. "Metastatic pattern and tumor sidedness in colorectal cancer." Journal of Clinical Oncology 37, no. 15_suppl (2019): e15147-e15147. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e15147.

Full text

Abstract:

e15147 Background: Tumor side has emerged as an important prognostic and predictive factor in metastatic colon cancer. We sought to study its impact on the metastatic pattern of colorectal cancer. Methods: The SEER database (version 8.3.5) was reviewed for patients with Stage IV colorectal cancer diagnosed between 2004-2015. We only included patients with labeled primary site, and excluded appendiceal, unlabeled and autopsy alone cases. Variables included in the analysis were: age, race, gender, grade, primary tumor side and sites of metastasis at diagnosis. Primary outcome analyzed was overal

APA, Harvard, Vancouver, ISO, and other styles

9

Que, Xuchu, John Samuelson, and Sharon Reed. "Molecular cloning of a rac family protein kinase and identification of a serine/threonine protein kinase gene family of Entamoeba histolytica." Molecular and Biochemical Parasitology 60, no. 2 (1993): 161–70. http://dx.doi.org/10.1016/0166-6851(93)90128-k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bustos, A., M. A. Cruz, P. Aramburo, et al. "Evaluation of clinical use of darbepoetin alfa in patients with chemotherapy-induced anemia." Journal of Clinical Oncology 27, no. 15_suppl (2009): e20585-e20585. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e20585.

Full text

Abstract:

e20585 Background: Chemotherapy-induced anemia (CIA) is a frequent complication of patients (pts) with cancer and could be treated with erythropoiesis-stimulating agents such darbepoetin alfa (DA). The aim of this study was to investigate the patterns of use and effect of DA to treat CIA in clinical practice conditions. Methods: This was an observational, retrospective, multicenter study performed in 58 Spanish centres. Eligible pts were ≥18 yrs, diagnosed with non-myeloid malignancies and treated with chemotherapy (CT) and DA from October 2005 to October 2006. Data on demographic and clinical

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "RFC 6815"

1

Bartoš, Patrik. "Testování přenosových parametrů internetového připojení." Master's thesis, Vysoké učení technické v Brně. Fakulta elektrotechniky a komunikačních technologií, 2021. http://www.nusl.cz/ntk/nusl-442361.

Full text

Abstract:

This thesis deals with methodology for measuring transmission parameters of internet connection. The aim of the thesis is to cover and compare known methods used for testing. Based on the research then design and realize an application that will provide those kind of measurements.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!